The consensus analyst price target for Avantor has edged up from $14.12 to $14.40, highlighting a modest increase in optimism regarding the company's future performance. This shift reflects a balance between renewed confidence from some analysts and continued caution amid ongoing macroeconomic headwinds. Stay tuned for insights on how to track these shifts and remain informed as Avantor's outlook continues to evolve.

Recent analyst commentary on Avantor highlights a mix of perspectives as Wall Street weighs the company's near-term challenges against its longer-term opportunities. The following sections break out the most notable bullish and bearish views as reported by major firms.

???? Bullish Takeaways

Raymond James raised its price target for Avantor from $14 to $16 and maintained an Outperform rating, signaling renewed confidence in the company’s ability to stabilize and recover over time.

The firm’s upward revision follows adjustments to its 2026-2027 outlook. This reflects expectations for gradual recovery or stabilization in Avantor’s end markets and aligns more closely with company commentary and consensus investor sentiment ahead of upcoming earnings.

Analysts continue to cite execution on cost controls and management’s transparency as positives that help position the company for improved future performance, even amid sector headwinds.

???? Bearish Takeaways

Morgan Stanley lowered its price target on Avantor from $15 to $12 after a challenging second quarter, maintaining an Equal Weight stance.

The firm pointed to ongoing bio processing headwinds resulting in a disappointing quarter and noted that competitive pressures may continue to weigh on Lab Solutions margins.

Reservations remain around valuation and the possibility that upside is already priced in, especially given near-term risks to growth and profitability.

Together, these perspectives show both the caution and optimism shaping Avantor’s current valuation and outlook as analysts await clearer signals from forthcoming earnings results.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Activist investor Engine Capital has taken a stake of roughly 3 percent in Avantor and is pushing the company to consider significant strategic changes. These could include a possible sale, a refresh of the board of directors, cost-cutting measures, or divestiture of noncore business units.

Engine Capital has indicated it believes Avantor could be valued between $17 and $19 per share in a potential sale. This range is notably higher than recent trading prices, and the investor may soon make its position and proposals public.

Morgan Stanley recently lowered its price target for Avantor from $15 to $12, citing ongoing challenges in the company’s bioprocessing segment. The bank noted that persistent competitive pressures are weighing on margins and contributed to the recent underperformance during the latest quarter.

The consensus analyst price target has increased slightly from $14.12 to $14.40. This reflects modestly improved outlooks.

The discount rate has risen marginally from 8.18% to 8.19%, which indicates slightly higher perceived risk or required return.

Revenue growth expectations have decreased from 2.49% to 2.36%. This suggests slightly lower anticipated sales expansion.

Net profit margin projections have declined from 6.43% to 6.05%, pointing to a modest downward adjustment in profitability assumptions.

The future P/E ratio estimate has increased from 26.62x to 28.88x. This indicates higher anticipated valuation relative to earnings.

Narratives are the smarter, story-driven way to invest. Instead of just crunching numbers, a Narrative connects Avantor’s business story to expert revenue and earnings forecasts, then distills it into a clear fair value. On Simply Wall St’s Community page, you can track these living Narratives, which are used by millions, to compare fair value to current price and get instant updates when the story changes.

See the full perspective in the original Avantor Narrative and keep up-to-date on:

How pharma contracts and R&D investment are driving Avantor’s long-term growth, even as margins face pressure.

Why Simply Wall St analysts expect competitive pricing and bioprocessing trends to shape future profitability and valuation.

What dynamic updates triggered by news and earnings mean for fair value and your buy or sell decisions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AVTR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com